Generex just got awarded two patents!

WORCESTER, Mass., Nov 19, 2008 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (GNBT) ( :: Generex Biotechnology Corporation ::), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has received two new patents, one in Mexico (issued by the Mexican Institute of Industrial Property), the other in New Zealand (issued by the Intellectual Property Office of New Zealand).
The patents share the title, "Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications," and contain claims to a pharmaceutical composition for pain relief containing a narcotic analgesic in micellar form.
"We are pleased that our patent portfolio is expanding to include the pain relief application," said Rose Perri, the Company's Chief Operating Officer. "As we continue the pivotal Phase III studies of our flagship product, Generex Oral-lyn(tm), we seek additional applications for our proprietary drug platform technology."
Generex currently holds an aggregate of 130 patents worldwide (21 of which are United States patents) and has an aggregate of 132 patent applications pending in various jurisdictions.